Recent Applications of Diversity-Oriented Synthesis Toward Novel, 3-Dimensional Fragment Collections

Fragment-based drug discovery (FBDD) is a well-established approach for the discovery of novel medicines, illustrated by the approval of two FBBD-derived drugs. This methodology is based on the utilization of small “fragment” molecules (<300 Da) as starting points for drug discovery and optimization. Organic synthesis has been identified as a significant obstacle in FBDD, however, in particular owing to the lack of novel 3-dimensional (3D) fragment collections that feature useful synthetic vectors for modification of hit compounds. Diversity-oriented synthesis (DOS) is a synthetic strategy that aims to efficiently produce compound collections with high levels of structural diversity and three-dimensionality and is therefore well-suited for the construction of novel fragment collections. This Mini-Review highlights recent studies at the intersection of DOS and FBDD aiming to produce novel libraries of diverse, polycyclic, fragment-like compounds, and their application in fragment-based screening projects.

[1]  Francesco Marchetti,et al.  Modular Synthesis of Diverse Natural Product‐Like Macrocycles: Discovery of Hits with Antimycobacterial Activity , 2017, Chemistry.

[2]  David R Spring,et al.  Identification of an anti-MRSA dihydrofolate reductase inhibitor from a diversity-oriented synthesis. , 2008, Chemical communications.

[3]  Nathan Brown,et al.  Fragment-based hit identification: thinking in 3D. , 2013, Drug discovery today.

[4]  Jia Luo,et al.  Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. , 2009, Cancer letters.

[5]  Andrea Basso,et al.  Diversity‐Oriented Synthesis of Various Enantiopure Heterocycles by Coupling Organocatalysis with Multicomponent Reactions , 2017 .

[6]  Harren Jhoti,et al.  Twenty years on: the impact of fragments on drug discovery , 2016, Nature Reviews Drug Discovery.

[7]  Patrick W. Faloon,et al.  Synthesis of a novel suppressor of beta-cell apoptosis via diversity-oriented synthesis. , 2011, ACS medicinal chemistry letters.

[8]  Sivaraman Dandapani,et al.  Efficient Routes to a Diverse Array of Amino Alcohol-Derived Chiral Fragments , 2016, ACS combinatorial science.

[9]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[10]  David R Spring,et al.  High content screening of diverse compound libraries identifies potent modulators of tubulin dynamics. , 2014, ACS medicinal chemistry letters.

[11]  Elena Lenci,et al.  Skeletal diversity from carbohydrates: use of mannose for the diversity-oriented synthesis of polyhydroxylated compounds. , 2015, The Journal of organic chemistry.

[12]  Nick Palmer,et al.  Design and synthesis of dihydroisoquinolones for fragment-based drug discovery (FBDD). , 2016, Organic & biomolecular chemistry.

[13]  Wolfgang H. B. Sauer,et al.  Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity , 2003, J. Chem. Inf. Comput. Sci..

[14]  Chanwoo Kim,et al.  Diversity-oriented synthetic strategy for developing a chemical modulator of protein–protein interaction , 2016, Nature Communications.

[15]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[16]  Wolfgang Jahnke,et al.  Fragment-based Drug Discovery Lessons and Outlook , 2016 .

[17]  Lakshmi B. Akella,et al.  Diversity-Oriented Synthesis Approach to Macrocycles via Oxidative Ring Expansion , 2012, Nature chemical biology.

[18]  Qing Cao,et al.  An improved model for fragment-based lead generation at AstraZeneca. , 2016, Drug discovery today.

[19]  S. Schreiber,et al.  Pairwise use of complexity-generating reactions in diversity-oriented organic synthesis. , 2000, Organic letters.

[20]  O. A. Davis,et al.  Synthesis of diversely functionalised 2,2-disubstituted oxetanes: fragment motifs in new chemical space. , 2015, Chemical communications.

[21]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[22]  Jesús Avila,et al.  GSK3 and tau: two convergence points in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[23]  Warren R. J. D. Galloway,et al.  Drug discovery: A question of library design , 2011, Nature.

[24]  Christopher W Murray,et al.  Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD). , 2016, Angewandte Chemie.

[25]  Stephen J Haggarty,et al.  Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β. , 2016, ACS medicinal chemistry letters.

[26]  Benito Munoz,et al.  Diversity-oriented synthesis yields novel multistage antimalarial inhibitors , 2016, Nature.

[27]  Adam Nelson,et al.  Design and synthesis of a fragment set based on twisted bicyclic lactams. , 2018, Bioorganic & medicinal chemistry.

[28]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[29]  Christopher W Murray,et al.  Efficient exploration of chemical space by fragment-based screening. , 2014, Progress in biophysics and molecular biology.

[30]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[31]  Stuart L. Schreiber,et al.  Discovery of a Small-Molecule Probe for V-ATPase Function , 2015, Journal of the American Chemical Society.

[32]  Stuart L Schreiber,et al.  A planning strategy for diversity-oriented synthesis. , 2004, Angewandte Chemie.

[33]  Stuart L. Schreiber,et al.  Stereochemical and Skeletal Diversity Arising from Amino Propargylic Alcohols , 2010, Organic letters.

[34]  Adam Nelson,et al.  Modular synthesis of thirty lead-like scaffolds suitable for CNS drug discovery. , 2017, Chemical communications.

[35]  Stuart L Schreiber,et al.  Towards the optimal screening collection: a synthesis strategy. , 2008, Angewandte Chemie.

[36]  A. H. Lipkus,et al.  Structural Diversity of Organic Chemistry. a Scaffold Analysis of the Cas Registry , 2022 .

[37]  Francesco Marchetti,et al.  Towards the systematic exploration of chemical space. , 2012, Organic & biomolecular chemistry.

[38]  Stephen D Pickett,et al.  Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia. , 2016, Journal of medicinal chemistry.

[39]  David R Spring,et al.  Diversity-oriented synthesis; a challenge for synthetic chemists. , 2003, Organic & biomolecular chemistry.

[40]  J. Bull,et al.  Regio- and Stereoselective Palladium-Catalyzed C(sp3)-H Arylation of Pyrrolidines and Piperidines with C(3) Directing Groups. , 2018, Organic letters.

[41]  P. Clemons,et al.  Route to three-dimensional fragments using diversity-oriented synthesis , 2011, Proceedings of the National Academy of Sciences.

[42]  David R Spring,et al.  A strategy for the diversity-oriented synthesis of macrocyclic scaffolds using multidimensional coupling. , 2013, Nature chemistry.

[43]  A. Bender,et al.  Diversity-oriented synthesis of macrocyclic peptidomimetics , 2011, Proceedings of the National Academy of Sciences.

[44]  Adam Nelson,et al.  Towards the realisation of lead-oriented synthesis. , 2014, Drug discovery today.

[45]  Stuart L. Schreiber,et al.  Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics , 2015, Proceedings of the National Academy of Sciences.

[46]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[47]  Adam Nelson,et al.  Synthesis and Demonstration of the Biological Relevance of sp3‐rich Scaffolds Distantly Related to Natural Product Frameworks , 2017, Chemistry.

[48]  W. Lubell,et al.  Diversity-Oriented Synthesis of Cyclic Azapeptides by A3 -Macrocyclization Provides High-Affinity CD36-Modulating Peptidomimetics. , 2017, Angewandte Chemie.

[49]  Andreas Bender,et al.  Synthesis of Structurally Diverse N‐Substituted Quaternary‐Carbon‐Containing Small Molecules from α,α‐Disubstituted Propargyl Amino Esters , 2018, Chemistry.

[50]  David A. Contreras-Cruz,et al.  Diversity-oriented synthesis of cyclopropyl peptides from Ugi-derived dehydroalanines , 2017 .

[51]  Andreas Bender,et al.  Anti-MRSA agent discovery using diversity-oriented synthesis. , 2008, Angewandte Chemie.

[52]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[53]  Stuart L. Schreiber,et al.  A small molecule that binds Hedgehog and blocks its signaling in human cells , 2009, Nature chemical biology.

[54]  Warren R. J. D. Galloway,et al.  Partially Saturated Bicyclic Heteroaromatics as an sp3‐Enriched Fragment Collection , 2016, Angewandte Chemie.

[55]  Sambasivarao Kotha,et al.  Diversity-oriented approaches to unusual α-amino acids and peptides: step economy, atom economy, redox economy, and beyond. , 2013, The Journal of organic chemistry.

[56]  Adam Nelson,et al.  Synthesis of Natural-Product-Like Molecules with Over Eighty Distinct Scaffolds** , 2008, Angewandte Chemie.

[57]  Adam Nelson,et al.  A systematic approach to diverse, lead-like scaffolds from α,α-disubstituted amino acids. , 2015, Chemical communications.

[58]  Anthony Wood,et al.  Organic synthesis provides opportunities to transform drug discovery , 2018, Nature Chemistry.